June 4, 2017 / 11:25 AM / 2 months ago

BRIEF-Merck KGaA enters immuno-oncology collaboration with F-Star

1 Min Read

June 4 (Reuters) - Merck KGaA

* Strengthens immuno-oncology portfolio through expansion of F-star collaboration including LAG-3/PD-L1 bispecific antibody- new strategic collaboration to develop and commercialize bispecific immuno-oncology antibodies

* Announced a new strategic collaboration with biopharmaceutical company F-star, Cambridge, UK, for development and commercialization of five bispecific immuno-oncology antibodies

* Beyond these five bispecific antibodies, Merck KGgaA, Darmstadt, Germany, will have further rights to replace, as well as to add to these antibodies using F-Star's bispecific antibody platform Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below